Volume 16, Number 3—March 2010
CME ACTIVITY - Dispatch
Extensively Drug-Resistant Mycobacterium tuberculosis from Aspirates, Rural South Africa
Table 1
Characteristic | Lymph node | Pleural fluid |
---|---|---|
Total no. patients | 34 | 33 |
Median age, y (IQR) | 31 (25–39) | 33 (28–39) |
Female sex, no. (%) |
18 (53) |
21 (64) |
HIV status, no. (%) | ||
Positive | 30 (88) | 24 (73) |
Negative | 1 (3) | 1 (3) |
Unknown |
3 (9) |
8 (24) |
Median CD4 cells/mm3 (IQR) |
128.5† (84–375) |
207‡ (118–334) |
Receiving ARVs,§ no. (% of HIV-infected) | ||
Yes | 14 (47) | 13 (54) |
No | 13 (43) | 10 (42) |
Unknown | 3 (10) | 1 (4) |
Median duration on ARVs, wk (IQR) |
8.4¶ (2.4–21.1) |
10.5# (5.8–55.1) |
History of prior TB, no. (%) | 8 (24) | 9 (27) |
Receiving TB treatment,§ no. (%) | 20 (59) | 18 (55) |
Median duration of TB treatment, wk (IQR) |
12** (4–16) |
6†† (3–14) |
Positive culture results, no. (%) | ||
M. tuberculosis | 12 (35) | 9 (27) |
Drug-susceptible TB, no. (% of M. tuberculosis) | 9 (75) | 3 (33) |
XDR TB, no. (%) | 1 (8) | 6 (67) |
Missing drug susceptibility results, no. (%) | 2 (17) | 0 |
Nontuberculous mycobacteria | 1 (3) | 0 |
Cryptococcus sp. | 0 | 1 (3) |
Other bacteria | 2 (6) | 1 (3) |
*IQR, interquartile range; ARVs, antiretroviral drugs; TB, tuberculosis; XDR TB, extensively drug-resistant TB.
†Available for 26 HIV-infected patients, excluding CD4% for 1 infant (36%).
‡Available for 18 HIV-infected patients.
§At time of aspirate collection.
¶Available for 10 of 14 patients receiving ARVs.
#Available in 12 of 13 patients receiving ARVs.
**Available for 9 patients.
††Available for 12 patients.
Page created: December 14, 2010
Page updated: December 14, 2010
Page reviewed: December 14, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.